ASH 2023 - FILO LAM

Interventions du FILO à l'ASH 2023 dans le domaine de la LAM

BIG-1

Current Results of Intensive Therapy in Younger Adults with Acute Myeloid Leukemia (AML): The Large Randomized French Backbone Intergroup (BIG)-1 Study on Behalf of the Filo, ALFA, and SFGM-TC Study Groups

Communication orale présentée par Mathilde HUNAULT

Number: 967
Presenter: Hunault-Berger Mathilde
Session: 615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Improving Intensive Chemotherapy Regimens for Treatment of AML
Time and Location: Monday, December 11, 2023: 4:30 PM-6:00 PM - San Diego Ballroom AB (Marriott Marquis San Diego Marina)

COVENIDAC

Venetoclax in Combination with Intermediate Doses of Cytarabine in Consolidation Phase for Acute Myeloid Leukemia Patients in First Complete Remission; Results of the Part 1 of the Phase 1/2 Multicentric Covenidac Study

Poster présenté par Pierre PETERLIN

Number: 4261
Presenter: Pierre Peterlin
Session: 615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster III
Time and Location: Monday, December 11, 2023: 6:00 PM-8:00 PM - Halls G-H (San Diego Convention Center)